title: The Impact of Trimetazidine Treatment on Left Ventricular Functions and Plasma Brain Natriuretic Peptide Levels in Patients with Non-ST Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
abstract: OBJECTIVE
  The aim of this study was to investigate the impact of treatment with oral trimetazidine (TMZ) applied before and after percutaneous coronary interventions (PCI) on short-term left ventricular functions and plasma brain natriuretic peptide (BNP) levels in patients with non-ST segment elevation myocardial infarction (NSTEMI) undergoing PCI.
  
  
  METHODS
  The study included 45 patients who were undergoing PCI with the diagnosis of NSTEMI. The patients were randomized into two groups. The first group (n=22) of the patients hospitalized with the diagnosis of NSTEMI was given conventional therapy plus 60 mg TMZ just prior to PCI. Treatment with TMZ was continued for one month after the procedure. TMZ treatment was not given to the second group (n=23). Echocardiography images were recorded and plasma BNP levels were measured just prior to the PCI and on the 1st and 30th days after PCI.
  
  
  RESULTS
  The myocardial performance index (MPI) was greater in the second group (p=0.02). In the comparison of BNP levels, they significantly decreased in both of the groups during the 30-day follow-up period (29.0±8 and 50.6±33, p<0.01 respectively). However, decreasing of BNP levels was higher in the group administered with TMZ. The decrease of left ventriclular end-diastolic volume was observed in all groups at 30 days after intervention, but was higher in the group administered with TMZ (p=0.01).
  
  
  CONCLUSIONS
  Trimetazidine treatment commencing prior to PCI and continued after PCI in patients with NSTEMI provides improvements in MPI, left ventricular end diastolic volume and a decrease in BNP levels.
authors: Department of Cardiology, Erzurum Regional Training and Research Hospital, Erzurum, Turkey.
authors: Selami
authors: S
authors: Demirelli
authors: Sule
authors: S
authors: Karakelleoğlu
authors: Fuat
authors: F
authors: Gündoğdu
authors: Muhammed Hakan
authors: MH
authors: Taş
authors: Ahmet
authors: A
authors: Kaya
authors: Hakan
authors: H
authors: Duman
authors: Hüsnü
authors: H
authors: Değirmenci
authors: Hikmet
authors: H
authors: Hamur
authors: Ziya
authors: Z
authors: Simşek
keywords: Natriuretic peptide, brain; Percutaneous coronary intervention; Trimetazidine
references: Int J Cardiol. 2007 Aug 9;120(1):79-84
references: 17134770
references: J Am Coll Cardiol. 2002 Aug 7;40(3):437-45
references: 12142108
references: Pharmacol Res. 2002 Jan;45(1):69-72
references: 11820865
references: Circulation. 1993 Feb;87(2):464-9
references: 8425293
references: N Engl J Med. 2000 Apr 20;342(16):1163-70
references: 10770981
references: Eur Heart J. 2001 Dec;22(24):2267-74
references: 11728147
references: Circ Res. 2000 Mar 17;86(5):580-8
references: 10720420
references: J Cardiovasc Pharmacol. 1993 Jan;21(1):128-35
references: 7678667
references: Am J Cardiovasc Drugs. 2007;7(2):143-50
references: 17503885
references: Curr Med Res Opin. 2004 Sep;20(9):1447-54
references: 15383193
references: Am J Hypertens. 1991 Nov;4(11):909-12
references: 1838692
references: Expert Opin Investig Drugs. 2002 May;11(5):615-29
references: 11996644
references: J Am Coll Cardiol. 2003 Dec 3;42(11):1917-20
references: 14662252
references: Am J Cardiol. 2006 Sep 4;98(5A):14J-18J
references: 16931201
references: Cardiovasc Res. 2007 Aug 1;75(3):536-45
references: 17559824
references: J Am Coll Cardiol. 2006 Sep 5;48(5):992-8
references: 16949492